科创板上市公司独立董事提名人声明与承诺 提名人奥精医疗科技股份有限公司董事会,现提名苏剑为奥精医疗科技股份 有限公司第三届董事会独立董事候选人,并已充分了解被提名人职业、学历、职 称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况。被提名人已 书面同意出任奥精医疗科技股份有限公司第三届董事会独立董事候选人(参见该 独立董事候选人声明）。提名人认为,被提名人具备独立董事任职资格,与奥精 医疗科技股份有限公司之间不存在任何影响其独立性的关系,具体声明并承诺 如下: 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、行政法规、 规章及其他规范性文件,具有五年以上法律、经济、会计、财务、管理等履行独 立董事职责所必需的工作经验。被提名人承诺参加证券交易所最近一期培训并取 得相关培训证明材料。 (一) 《中华人民共和国公司法》等关于董事任职资格的规定; (二) 《中华人民共和国公务员法》关于公务员兼任职务的规定(如适用); (三)中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定; 二、被提名人任职资格符合下列法律、行政法规和部门规章的要求: ...

在公司股东大会审议通过取消监事会事项前，公司第二届监事会仍将严格按照 《公司法》《证券法》等法律、法规、规章和规范性文件的要求，勤勉尽责履行监督 职能，继续对公司经营、公司财务及公司董事、高级管理人员履职的合法合规性进 行监督，维护公司和全体股东的利益。 1 二、关于增加公司注册资本的情况 证券代码：688613 证券简称：奥精医疗 公告编号：2025-057 奥精医疗科技股份有限公司 关于取消监事会、增加注册资本并修订《公司章程》及 制定、修订部分治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司 "）于2025年11月10日召开了第 二届董事会第十七次会议，审议通过了《关于取消监事会、增加注册资本并修订〈 公司章程〉的议案》及《关于制定、修订公司部分治理制度的议案》。为符合对上 市公司的规范要求，进一步完善公司治理，根据2024年7月1日起实施的《中华人民共 和国公司法》（以下简称"《公司法》"）、《关于新公司法配套制度规则实施相关过 渡期安排》《上市公司章程指引（ ...

科创板上市公司独立董事候选人声明与承诺 本人李晓明，已充分了解并同意由提名人奥精医疗科技股份有限公司董事 会提名为奥精医疗科技股份有限公司第三届董事会独立董事候选人。本人公开声 明，本人具备独立董事任职资格，保证不存在任何影响本人担任奥精医疗科技股 份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有五年以上法律、经济会计、财务、管理等履行独立董 事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （三）中国证监会《上市公司独立董事管理办法》和上海证券交易所自律监 管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定（如 适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼职（任职） 问题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐倡廉建设的 意见》的相关规定（如适用）； （七）中国人民银 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-060 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第三次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 26 日 14 点 30 分 奥精医疗科技股份有限公司 召开地点：北京市大兴区生物医药产业基地庆丰西路 69 号 35 号楼 3 层 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 26 日 至2025 年 11 月 26 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年11月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2025-058 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 奥精医疗科技股份有限公司（以下简称"公司"）第二届监事会第十六次会 议于 2025 年 11 月 10 日以现场表决的方式召开。会议通知已通过邮件的方式送 达各位监事。本次会议应出席监事 3 人，实际出席监事 3 人，会议由监事会主席 吴永强主持。会议的召集和召开程序符合有关法律、法规、规章和《奥精医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事认真审议，作出如下决议： 审议通过《关于取消公司监事会、增加注册资本并修订〈公司章程〉的议案》 （一）取消监事会情况 根据《公司法》《关于新公司法配套制度规则实施相关过渡期安排》《上市 公司章程指引》等有关法律法规和规范性文件的规定，并结合公司实际情况，公 司将不再设置监事会与监事，由董事会审计委员会行使《公司法》规定的监事会 的职权，《奥精医疗科技股份有限公司监事会议事规则》相应废止，公司各 ...

Core Viewpoint - Aojing Medical (688613) has experienced a decline in stock price and significant shareholder changes, while showing positive financial performance in its recent quarterly report [1][3][5]. Shareholder Changes - BioVeda China RMB Investment Limited reduced its holdings by 966,600 shares, accounting for 0.7055% of the total share capital, during a period when the company's stock price fell by 14.62% [3][6]. - As of September 30, 2025, the number of shareholders increased to 9,862, a rise of 15.44% compared to June 30, 2025, with the average shareholding decreasing from 16,000 shares to 13,900 shares [4][8]. Financial Performance - For the first three quarters of 2025, Aojing Medical reported a main revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, up 185.19% [5][8]. - In the third quarter alone, the company achieved a main revenue of 56.02 million yuan, reflecting a year-on-year growth of 16.54%, and a net profit of 5.97 million yuan, which is a 237.64% increase compared to the same period last year [5][8]. - The company's debt ratio stands at 6.22%, with a gross profit margin of 68.9% [5]. Company Announcements - Aojing Medical has completed the reduction plan by BioVeda, which involved selling 1,355,515 shares at prices ranging from 23.00 to 28.12 yuan per share, totaling approximately 33.55 million yuan [6][8]. - The company has concluded the fundraising project for "Mineralized Collagen/Polyester Artificial Bone and Collagen Sponge R&D," with a surplus of 523,800 yuan intended for permanent replenishment of working capital [7][8].

Core Viewpoint - Aojing Medical, a leading company in high-end biomedical materials and related medical devices in China, is facing short-term performance pressure due to centralized procurement but is expected to accelerate market expansion and maintain strong growth momentum [6]. Group 1: Company Overview - Aojing Medical was established on December 22, 2004, and was listed on the Shanghai Stock Exchange on May 21, 2021. The company is headquartered in Beijing and specializes in the research, production, and sales of high-end biomedical materials and related medical devices [1]. - The company operates in the pharmaceutical and biomedical industry, specifically in the medical device and consumables sector, with concepts including medical devices, oral healthcare, small-scale nuclear fusion, superconductivity, and nuclear power [1]. Group 2: Financial Performance - In Q3 2025, Aojing Medical achieved a revenue of 156 million yuan, ranking 50th among 50 companies in the industry. The top company, Yingke Medical, reported a revenue of 7.425 billion yuan, while the industry average was 1.379 billion yuan [2]. - The net profit for the same period was approximately 10.60 million yuan, placing the company 43rd in the industry. The leading company, Lepu Medical, reported a net profit of 999.6 million yuan, with the industry average at 183 million yuan [2]. Group 3: Financial Ratios - Aojing Medical's debt-to-asset ratio was 6.22% in Q3 2025, down from 7.53% year-on-year and significantly lower than the industry average of 23.66%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 68.90%, a decrease from 74.46% year-on-year but still above the industry average of 48.78%, reflecting robust profitability [3]. Group 4: Executive Compensation - The chairman, Hu Gang, received a salary of 1.6835 million yuan in 2024, a slight increase from 1.6822 million yuan in 2023. The general manager, Qiu Zhiye, earned 1.4528 million yuan, up from 1.3802 million yuan in the previous year [4]. Group 5: Shareholder Information - As of September 30, 2025, the number of A-shares shareholders increased by 15.44% to 9,862, while the average number of shares held per shareholder decreased by 13.37% to 13,900 shares [5]. Group 6: Market Outlook - According to Cinda Securities, Aojing Medical's performance is under short-term pressure due to centralized procurement, but the company is accelerating its market expansion. Key highlights include the development of over 900 new hospitals in 2024 and international expansion breakthroughs [6]. - The company expects significant revenue growth from its "Gaojin" product line and the acquisition of HumanTechDental, which will enhance its oral implant business. Revenue projections for 2025-2027 are 270 million, 355 million, and 470 million yuan, with corresponding net profits of 42 million, 66 million, and 98 million yuan [6].

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Core Insights - The company reported a total revenue of 156 million yuan for Q3 2025, ranking 101 among disclosed peers [1] - The net profit attributable to shareholders was 13.94 million yuan, ranking 78 among disclosed peers [1] - The net cash inflow from operating activities was -4.50 million yuan, ranking 88 among disclosed peers [1] Financial Metrics - The latest debt-to-asset ratio is 6.22% [3] - The latest gross profit margin is 68.90%, a decrease of 5.56 percentage points compared to the same period last year [3] - The latest return on equity (ROE) is 0.97%, ranking 77 among disclosed peers [3] - The diluted earnings per share (EPS) is 0.10 yuan, ranking 68 among disclosed peers [3] - The latest total asset turnover ratio is 0.10 times, ranking 98 among disclosed peers [3] - The latest inventory turnover ratio is 0.69 times, a decrease of 0.35 times compared to the same period last year, representing a year-on-year decline of 33.46% [3] Shareholder Information - The number of shareholders is 9,862, with the top ten shareholders holding 51.88 million shares, accounting for 37.87% of the total share capital [3]

Core Viewpoint - The company has announced the completion of certain fundraising projects and the permanent allocation of surplus funds to supplement working capital, along with the cancellation of related fundraising accounts [8][9][12]. Financial Data - The company reported that the total amount raised from the public offering was approximately RMB 547.67 million, with net proceeds after deducting issuance costs amounting to approximately RMB 500.82 million [8]. - The company has stated that the fundraising project "Mineralized Collagen/Polyester Artificial Bone and Collagen Sponge R&D Project" has been completed, and the surplus funds will be used to permanently supplement working capital [9][12]. Fundraising Project Details - The company has decided to conclude the aforementioned fundraising project and will cancel the related fundraising accounts, which will not affect the normal operation of the fundraising project [13]. - The surplus funds amount to approximately RMB 523,800, including interest income, which will be used for daily operational activities [12]. Opinions from Supervisory and Sponsoring Institutions - The supervisory board believes that the decision to conclude certain fundraising projects and allocate surplus funds is beneficial for improving the efficiency of fund usage and reducing financial costs, aligning with the interests of all shareholders [14]. - The sponsoring institution, Huatai United Securities, has confirmed that the decision-making process was properly followed and supports the allocation of surplus funds as a prudent decision that optimizes resource allocation [15].